Compounds > actisomide
Page last updated: 2024-12-11

actisomide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SC 36602: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917898
CHEMBL ID561826
SCHEMBL ID121854
MeSH IDM0147362

Synonyms (27)

Synonym
sc-36602
actisomide
96914-39-5
D02762
actisomide (usan/inn)
sc 36602
CHEMBL561826
(4r,4ar)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4ah-pyrido[1,2-c]pyrimidin-3-one
ijq29n87nr ,
actisomida
actisomidum [inn-latin]
unii-ijq29n87nr
actisomida [inn-spanish]
actisomide [usan:inn]
3h-pyrido(1,2-c)pyrimidin-3-one, 4-(2-(bis(1-methylethyl)amino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, cis-(+-)-
actisomidum
(+-)-cis-4-(2-(diisopropylamino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3h-pyrido(1,2-c)pyrimidin-3-one
actisomide [inn]
actisomide [usan]
3h-pyrido(1,2-c)pyrimidin-3-one, 4-(2-(bis(1-methylethyl)amino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, cis-(+/-)-
(+/-)-cis-4-(2-(diisopropylamino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3h-pyrido(1,2-c)pyrimidin-3-one
SCHEMBL121854
(4r)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4ah-pyrido[2,1-f]pyrimidin-3-one
Q15633951
(4r,4ar)-4-(2-(diisopropylamino)ethyl)-1-methyl-4-phenyl-4,4a,5,6,7,8-hexahydro-3h-pyrido[1,2-c]pyrimidin-3-one
DTXSID001026019
3h-pyrido[1,2-c]pyrimidin-3-one, 4-[2-[bis(1-methylethyl)amino]ethyl]-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, (4r,4ar)-rel-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis."( Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers.
Dean, RR; Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Sketch, MH; Stoysich, A, 1991)		0.54
" The terminal half-life of actisomide was similar (1."( Pharmacokinetics of a novel antiarrhythmic drug, actisomide.
Anderson, S; Cook, CS; Karim, A; Rozek, LF; Schoenhard, GL; Stolzenbach, J, 1993)		0.84

Dosage Studied

ExcerptRelevanceReference
" Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group."( Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers.
Dean, RR; Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Sketch, MH; Stoysich, A, 1991)		0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		1.971011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		4.4651
ConditionIndicatedRelationship StrengthStudiesTrials
Arrhythmia
[description not available]		01.9710
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		01.9710